[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335032-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335032-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-term-outcome-of-definitive-radiotherapy-for-locally-advanced-non-small-cell-lung-cancer-a-real-world-single-center-study-in-the-pre-durvalumab-era","Long-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer - A real-world single-center study in the pre-durvalumab era","","Background: Limited large-scale evidence in China exists for locally advanced non-small cell lung cancer (LA-NSCLC) treated with radical radiotherapy (RT). This study evaluates overall survival, progression-free survival, treatment effectiveness, and toxicity for LA-NSCLC patients receiving definitive RT before the durvalumab era. Methods: A retrospective analysis of 789 patients treated between January 2005 and December 2015 used Kaplan–Meier and log-rank tests for survival comparisons and Cox regression for multivariate analysis.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-term-outcome-of-definitive-radiotherapy-for-locally-advanced-non-small-cell-lung-cancer-a-real-world-single-center-study-in-the-pre-durvalumab-era/335032/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-term-outcome-of-definitive-radiotherapy-for-locally-advanced-non-small-cell-lung-cancer-a-real-world-single-center-study-in-the-pre-durvalumab-era/335032.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What question does the study address about LA-NSCLC?","Question",{"text":63,"@type":64},"It assesses long-term survival, treatment effectiveness, and toxicity in LA-NSCLC patients treated with definitive radiotherapy in China during the pre-durvalumab era.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were outcomes analyzed in this research?",{"text":68,"@type":64},"Survival comparisons used the Kaplan–Meier method and log-rank test, while Cox regression was used for multivariate analysis of prognostic factors.",{"name":70,"@type":61,"acceptedAnswer":71},"Which factors were associated with overall survival and progression-free survival?",{"text":72,"@type":64},"For overall survival, Karnofsky Performance Status score, smoking status, and combined chemotherapy were prognostic factors. For progression-free survival, combined chemotherapy and radiation dose were prognostic factors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335032,1790012972,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":4},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","DOI: 10. 1002/cam4 .70051  \nRESEAR CH ARTICLE  \nLong-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer: A real-world singlecenter study in the pre-durvalumab era  \nHong Zhu1,2  | Yi Xu1 | Huiquan Gao1 | Xingwen Fan1,3,4,5  |  \nMing Fan1,3,4,5 | Kuaile Zhao1,3,4,5  | Huanjun Yang1,3,4,5 | Zhengfei Zhu1,3,4,5  | Kailiang Wu1,3,4,5  \n1Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China 2Department of Radiation Oncology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China 3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China  \n4Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China 5Shanghai Key Laboratory of Radiation Oncology, Shanghai, China  \nCorrespondence  \nKailiang Wu, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Shanghai 200032, China. [Email:](Email: wukailiang@aliyun.com)[ wukailiang@aliyun.com](Email: wukailiang@aliyun.com)  \nFunding information  \nThe Key-Area Research and Development of Guangdong Province, Grant/Award Number:  \n2020B1111190001; Key Clinical Specialty Project of Shanghai  \nAbstract  \nBackground: There was limited research data on large-scale locally advanced non-small cell lung cancer (LA-NSCLC) radical radiotherapy (RT) reported in China. This study examined overall survival (OS), progression-free survival (PFS), treatment effectiveness, and toxicity in patients with LA-NSCLC treated with definitive RT in the pre-durvalumab era.  \nMethods: A retrospective analysis of demographic information, clinical characteristics, treatment patterns, and clinical outcomes of 789 patients with LANSCLC who underwent radical RT at our center between January 2005 and December 2015 was performed. The Kaplan–Meier method and log-rank test were used for survival comparisons, and Cox regression was used for multivariate analysis.  \nResults: There were 328 patients with stage IIIA disease and 461 with stage IIIB disease. By the last follow-up, there were 365 overall deaths and 576 cases of recurrence, metastasis, or death. The median survival time was 31 months. The OS rates at 1, 2, 5, and 10 years were 83.7%, 59.5%, 28.8%, and 18.9%, respectively. PFS rates at 1, 2, 5, and 10 years were 48%, 24.5%, 11.9%, and 5.5%, respectively. Rates of ≥grade 3 acute radiation pneumonitis or esophagitis were 7.6% and 1.9%, respectively. Rates of ≥grade 3 chronic radiation pneumonitis and esophagitis were 11% and 0.4%, respectively. Multivariate analysis showed that the Karnofsky Performance Status (KPS) score, smoking status, and combined chemotherapy were prognostic factors for OS (p \u003C0.05) . Multivariate analysis revealed that combined chemotherapy and radiation dose were prognostic factors for PFS (p \u003C0.05) . Conclusions: Our center's data showed that the survival prognosis of locally advanced patients receiving RT and chemotherapy in China was consistent with international levels during the same period. Patients with a KPS score of 80 or higher, who had never smoked or received combined RT, had a more favorable  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine. 2024;13:e70051 .  \n[https://doi.org/10.1002/cam4.70051](https://doi.org/10.1002/cam4.70051)  \n[wileyonlinelibrary.com/journal/cam4](wileyonlinelibrary.com/journal/cam4)  \n1 of 12  \nprognosis than those with a KPS of less than 80, who had smoked, or only received RT. The combination of RT and chemotherapy, with a reasonable radiation dose, was the key to improving the therapeutic effect.  \nKEYWORDS  \nchemoradiotherapy, definitive radiotherapy, locally advanced non-small cell lung cancer, prognostic factors, treatment outcome  \n1 | INTRODUCTI","cbCaiksnChRlFnKe","https://ap.wps.com/l/cbCaiksnChRlFnKe","pdf",1411923,12,"English","# Introduction\n## Treatment standards and prognostic context\n# Methods\n## Study design and statistical approach\n# Results\n## Survival outcomes and toxicity","[{\"question\":\"What question does the study address about LA-NSCLC?\",\"answer\":\"It assesses long-term survival, treatment effectiveness, and toxicity in LA-NSCLC patients treated with definitive radiotherapy in China during the pre-durvalumab era.\"},{\"question\":\"How were outcomes analyzed in this research?\",\"answer\":\"Survival comparisons used the Kaplan–Meier method and log-rank test, while Cox regression was used for multivariate analysis of prognostic factors.\"},{\"question\":\"Which factors were associated with overall survival and progression-free survival?\",\"answer\":\"For overall survival, Karnofsky Performance Status score, smoking status, and combined chemotherapy were prognostic factors. For progression-free survival, combined chemotherapy and radiation dose were prognostic factors.\"}]","Long-term outcome of definitive radiotherapy for locally advanced non-small cell lung cancer - A real-world single-center study in the pre-durvalumab era | PDF",1790009381]